C reactive Protein Test
C reactive protein is an acute phase reactant produced by the liver as an inflammatory response because of an infection. C reactive protein determination detects the presence of inflammation in the body. C-reactive protein values are very significant in determining the possibilities of long term diseases such as myocardial infarction, neoplastic proliferation and also some inflammatory diseases caused due to infection. C-reactive protein is also considered as the scavenger protein. It binds to many microorganisms in facilitating the process of cell mediated cytotoxicity and also phagocytosis.
C reactive protein test is advised to patients who undergo surgeries pertaining to both general and transplantation categories. It enables in determining the underlying causes of graft rejection. The general CRP determination is of less significance as the values obtained may not describe the underlying health conditions in a specific way. This diagnostic obligation pertaining to the exact values of CRP is eliminated with the introduction of highly sensitive C-reactive protein test (HsCRP).
Principle of the Hs-CRP test
Highly sensitive CRP test is ordered especially in the diagnosis of cardiovascular disease. Hs-CRP test is done using the enzyme linked immunosorbent assay (ELISA). The procedure involves the use of a unique monoclonal antibody which is targeted against a distinct antigenic determinant on the CRP. The CRP molecules in the test sample are sandwiched between the monoclonal antibody which forms the solid phase for immobilization in the test and the enzyme linked antibodies.
Physiology and clinical manifestations
The CRP levels in the body significantly increase after 24 to 48 hours as a response to indicate the onset of tissue damage. These values may remain constant for a longer duration before they reach the normal values. The American Heart Association and the Center for Disease Control have determined the risk groups based on the CRP values. Patients with CRP value less than 1mg/L fall under the low risk groups and values ranging from 1 to 3 mg/L indicate the patients fall under average and high risk groups for cardio vascular disease.
The values of high sensitivity C reactive protein test are part of cardiovascular disease diagnosis. These values are further correlated with other important parameters such as cholesterol levels and glucose levels. Careful analysis is required to understand the history of the patient before the test. This analysis includes a previous history of smoking, infectious disease, alcoholism etc. The hsCRP level values vary if the patient has previously taken non steroidal anti inflammatory drugs. High sensitivity CRP ratios have exceptions in clinical conditions such as arthritis because of the high inflammatory response seen in these conditions. The values are not taken into consideration under these conditions. Coronary artery disease related conditions are predicted in healthy individuals through the hsCRP test.
This Hs CRP test serves as an effective marker in identifying the risk for coronary artery related stroke or heart attack in a healthy individual. The hs-CRP test is also used in the detection of colon cancer and complications related to diabetes and obesity. The hs-CRP test is increasingly becoming an effective test in the pharmacological management of patients by the clinicians as it gives details for the precise use of statins and anti thrombotic medications. Research pertaining to the comparative ratio drawn between patients having high CRP values and low LDL (low density lipoproteins) values prove that these patients are at greater risk of developing cardiovascular disease. These studies conclude that the hs-CRP test is a significant marker in prediction of asymptomatic cardiovascular disease among healthy individuals. The hs-CRP test is also effective in the determination of HNF1A mutations which act as the precursor for the maturity onset diabetes of the young (MODY). This helps in the screening of unidentified diabetes.
Thrombocytosis refers to a hematological condition in which the accumulation of platelets causes many medical emergencies such as stroke and cardiac complications. Platelets are responsible for regulating and facilitating the mechanism of blood clot formation, also known as thrombus. The elevated level of platelets is associated with disorders of blood or bone marrow in which blood cells are produced. The abnormalities can lead to many hematological disorders, Thrombocytosis being one of the most noticed.
Classification and Clinical manifestations
Thrombocytosis can be classified in to two types depending upon the origin of its occurrence:
Primary thrombocytosis: Primary thrombocytosis is caused by abnormalities associated with bone marrow or blood. It is commonly known as essential thrombocythemia. This disorder is predominantly noticed in women and adults above the age of 55. The clinical symptoms associated with disease include erythromelalgia where there is redness of the arms and legs with burning sensation and pain. In addition to this, lightheadedness, nausea, weakness, lethargy, dizziness, frequent nosebleeds and bloody stools follow depending upon the stage of the thrombocytosis. Pathological smears usually indicate the presence of megakaryocytic cells in the blood smear, which are produced by the bone marrow in excess. Studies indicate the genetic evidence of the Janus kinase 2 (JAK 2)mutation in thrombocytic patients, which also associate, with neoplasms of proliferative origin leading to ischemia and heart attack.
Secondary Thrombocytosis: This form of thrombocytosis is reactive in nature and it is caused by the excessive production of the pro-inflammatory interleukins such as IL-1 and IL-6. In this condition, C reactive protein is noticed in excess in the serum and typically indicating the onset of inflammatory disease. It is one of the common conditions in the United States and the complications associated with it are related to vascular obstructions. Secondary thrombocytosis is caused because of various underlying conditions such as infections, trauma, splenectomy, malignancy and anemia associated with iron deficiency.
Diagnosis and Treatment
Thrombocytosis is diagnosed by blood tests to determine the amount of megakaryocytic in the blood film. Complete blood count with platelet amount evaluation along with C protein reactivity is studied. Splenomegaly is noticed in nearly 25% of patients. Abnormal platelet values may be over 2,000,000/mcL. The common medications prescribed for thrombocytosis are hydroxyurea, anagrelide and introns. Some of the noticed side effects are associated with leukemia and hence the dosage is very important to avoid additional complications such as dizziness, diarrhea and vomiting.
CRP blood test
CRP (C-Reactive Protein) blood test measures the levels of a special protein produced by the liver during infection or acute inflammation. Usually blood does not contain CRP. CRP blood tests are often done to diagnose rheumatic fever, cancer, tuberculosis, pneumonia or heart attack. Often CRP test is suggested along with ESR blood test to check for rheumatoid arthritis and lupus. Pregnant women or women on oral contraceptives may notice positive CRP in the blood. Since CRP blood test is indicative of inflammation in the blood, it is an important predictor of heart problems.
This blood test aids in detecting the risk of developing myocardial infarction. In patients suffering acute coronary syndrome, the hsCRP test can predict the risk of developing cardiovascular disease or ischemia. The reference range for hsCRP:
Low Risk: < 1 mg/L
Average Risk: 1 - 3 mg/L
High Risk: >3 mg/L
Acute inflammation: >10 mg/L
Enter your health or medical queries in our Artificial Intelligence powered Application here. Our Natural Language Navigational engine knows that words form only the outer superficial layer. The real meaning of the words are deduced from the collection of words, their proximity to each other and the context.
Diseases, Symptoms, Tests and Treatment arranged in alphabetical order:
Bibliography / Reference
Collection of Pages - Last revised Date: December 13, 2019